UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. SPCX
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS
(NASDAQ: IMUX) Delayed: 15.21 +0.46 (3.12%)
Previous Close $14.75    52 Week High $ 
Open $14.48    52 Week Low $ 
Day High $15.41    P/E N/A 
Day Low $14.12    EPS $ 
Volume 23,087